Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 4/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4336028 | 0.89 | F2R (0.47) | F2RS1PR2MAOBBCHEMAOA | |
| Trifluoroacetic Acid SCHEMBL4336036 | 0.89 | F2R (0.47) | F2RS1PR2MAOBBCHEMAOA | |
| SCHEMBL13785124 | 0.89 | F2R (0.50) | F2RS1PR2MAOBBCHEMAOA | |
| SCHEMBL6752883 | 0.75 | F2R (0.56) | F2RMAPTKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4340442 | 0.74 | F2R (0.50) | F2RS1PR2MAPTKMT2AKDM4E | |
| SCHEMBL13785122 | 0.74 | F2R (0.54) | F2RS1PR2MAOBBCHEMAOA | |
| Bromide SCHEMBL4346208 | 0.73 | F2R (0.53) | F2RS1PR2MAOBBCHEMAOA | |
| Bromide SCHEMBL4346207 | 0.73 | F2R (0.53) | F2RS1PR2MAOBBCHEMAOA | |
| SCHEMBL14369048 | 0.72 | F2R (0.57) | F2RS1PR2KMT2AMAOBBCHE | |
| SCHEMBL4338978 | 0.70 | F2R (0.49) | F2RMAPTKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | H1-2, H1-3, H1-4 | F2R 2393/4885S1PR2 1573/4885MAPT 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.